Amgen Inc. (AMGN)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
173.53-1.27 (-0.73%)
At close: 4:00 PM EDT
People also watch:
BIIBGILDCELGMRKBMY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open174.22
Prev Close174.80
Bid172.00 x 100
Ask174.04 x 400
Day's Range172.83 - 174.42
52wk Range131.43 - 176.85
1y Target EstN/A
Market Cap129.86B
P/E Ratio (ttm)17.76
Beta1.34
Volume1,548,409
Avg Vol (3m)2,847,721
Dividend & Yield4.00 (2.29%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswire8 hours ago

    Amgen Opens Nomination Process For LabCentral Residency

    CAMBRIDGE, Mass., Sept. 26, 2016 /PRNewswire/ -- Amgen (AMGN) today announced that the nomination process to submit proposals to receive an Amgen-sponsored LabCentral Golden Ticket is open for interested life-sciences and biotech startup companies in Massachusetts. LabCentral is an innovative, shared laboratory space designed as a launch pad for premier high-impact life-sciences and biotech startups. As one of LabCentral's platinum sponsors, Amgen can nominate up to two early-stage companies each year to take up residence in LabCentral's Kendall Square facilities in Cambridge, Mass.

  • TheStreet.com9 hours ago

    Wall Street Sells Off on Worries Over Clinton-Trump Showdown

    Stocks end Monday's session sharply lower as Wall Street grows restless ahead of the first presidential debate.

  • PR Newswire9 hours ago

    Amgen And UCB Announce U.S. FDA Acceptance Of Biologics License Application For Romosozumab

    THOUSAND OAKS, Calif. and BRUSSELS, Sept. 26, 2016 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for romosozumab, an investigational monoclonal antibody for the treatment of osteoporosis in postmenopausal women at increased risk of fracture. "We believe romosozumab could serve as an important therapeutic option for osteoporosis patients with an increased risk of fracture," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. The BLA, submitted on July 19, 2016, is based on data from the pivotal Phase 3 placebo-controlled FRActure study in postmenopausal woMen with ostEoporosis (FRAME) in approximately 7,200 patients.